Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Atrial Fibrillation (AF)

In brief

A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.

Key facts

Study ID

NCT05712200

Run by

Anthos Therapeutics, Inc.

People needed

2500

Starts

2022-12-27

Expected to finish

2027-12-30

Last updated by the study team

2026-07-13

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is able to understand and has provided written informed consent to participate in the trial
• Diagnosed Atrial Fibrillation (AF) or atrial flutter (documented on an electrocardiogram (ECG) or monitor recording)
• Age 65-74 and a CHA2DS2VASc ≥4 OR age ≥75 and a CHA2DS2VASc ≥3
• Patient is judged by the responsible physician to be unsuitable for oral anticoagulation because the risks outweigh the benefits or the patient is unwilling to take oral anticoagulation AND this determination was made prior to and independent of the study
• At least 1 bleeding risk factor such as severe renal insufficiency, planned daily use of antiplatelet medication for the duration of the trial, history of bleeding from a critical area, or other conditions associated with increased risk of bleeding such as chronic nonsteroidal anti-inflammatory drug (NSAID) use, frailty or multiple falls
• Patient is judged by the responsible physician to be unsuitable for left atrial appendage (LAA) closure or occlusion device, an approved device is not available, or the patient is unwilling to undergo the procedure AND this determination was made prior to and independent of the study

You may not qualify if…

• AF due to an ongoing acute reversible cause (e.g., cardiac surgery, pulmonary embolism (PE), untreated hyperthyroidism, alcohol use)
• Patients who within 60 days prior to randomization (1) received a vitamin K antagonists (VKA) (e.g., warfarin, phenprocoumon, acenocoumarol) or a direct oral anticoagulant (DOAC) such as, dabigatran, rivaroxaban, apixaban, or edoxaban or (2) were newly diagnosed with AF
• Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral hemorrhage at any time in the absence of antithrombotic treatment
• Any stroke within 14 days before randomization or transient ischemic attack (TIA) within 3 days before randomization
• Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or invasive) during the course of the study
• Patients on dialysis at screening or who are planned to start dialysis within 6 months
• Other protocol defined Inclusion/Exclusion criteria may apply

Where it is running

• Anthos Investigational site 9818 — Clearwater, Florida, United States (enrolling)
• Anthos Investigative Site 1025 — Clearwater, Florida, United States (enrolling)
• Anthos Investigative Site 1013 — Boca Raton, Florida, United States (enrolling)
• Anthos Investigational site 9810 — Bradenton, Florida, United States (enrolling)
• Anthos Investigative Site 1099 — Peoria, Arizona, United States (enrolling)
• Anthos Investigative Site 1040 — Birmingham, Alabama, United States (enrolling)
• Anthos Investigative Site 1041 — Mobile, Alabama, United States (enrolling)
• Anthos Investigative Site 9934 — Altamonte Springs, Florida, United States (enrolling)
• Anthos Investigative Site 9959 — Imperial, California, United States (enrolling)
• Anthos Investigational site 9939 — Birmingham, Alabama, United States (enrolling)
• Anthos Investigative Site 1078 — Loma Linda, California, United States (enrolling)
• Anthos Investigative Site 1077 — Los Angeles, California, United States (enrolling)
• Anthos Investigative Site 9906 — Phoenix, Arizona, United States (enrolling)
• Anthos Investigational site 9821 — Orange, California, United States (enrolling)
• Anthos Investigative Site 9927 — Yuma, Arizona, United States (enrolling)
• Anthos Investigative Site 1071 — San Dimas, California, United States (enrolling)
• Anthos Investigative Site 9929 — Huntington Beach, California, United States (enrolling)
• Anthos Investigative Site 9938 — Santa Rosa, California, United States (enrolling)
• Anthos Investigative Site 9908 — South Gate, California, United States (enrolling)
• Anthos Investigative Site 9907 — Vista, California, United States (enrolling)
• Anthos Investigative Site 1095 — Aurora, Colorado, United States (enrolling)
• Anthos Investigative Site 9921 — Lancaster, California, United States (enrolling)
• Anthos Investigative Site 9922 — Golden, Colorado, United States (enrolling)
• Anthos Investigative Site 1012 — Stamford, Connecticut, United States (enrolling)
• Anthos Investigative Site 1022 — Clearwater, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.